Results 51 to 60 of about 5,430 (178)

Engineered Metal–Organic Frameworks‐Based Materials for Environmental Detection

ENERGY &ENVIRONMENTAL MATERIALS, Volume 9, Issue 4, July 2026.
Engineered metal–organic frameworks (MOFs) regulated by various material modification strategies are discussed for environmental contaminant detection under different sensing mechanisms, providing future improvements of MOFs in environmental detection. Sensitive and selective detection of contaminants is crucial for environmental protection.
Pan Gao, Song Wang, Yuechao Yao, Yibo Dou   +3 more
wiley   +1 more source

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat

, 2017
Contains fulltext : 169944.pdf (Publisher’s version ) (Open Access)BACKGROUND: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir.
Burger, D.M., Kanter, C.T.M.M. de, Smolders, E.J., Colbers, E.P.H., Velthoven-Graafland, K., Drenth, J.P.H., Smolders, E J, Colbers, E P H, de Kanter, C T M M, Burger, D M, Velthoven-Graafland, K, Drenth, J P H   +11 more
core   +1 more source

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region [PDF]

International Journal of Advanced Humanities Research
The liver is the largest organ in the body, located below the diaphragm and protected by the lower ribs of the rib cage (Johns Hopkins Medicine, 2022).
Fahad Alghamdi, Rashed Mohammed
doaj   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY

, 2018
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in ...
CH. V. S Gautam*, N. Harika, V. Balaji, V. Srinivas Prasad
core   +1 more source

IMPACT OF DIABETIC CONTROL ON ACHIEVING SUSTAINED VIROLOGIC RESPONSE IN CHRONIC HCV PATIENTS RECEIVING DIRECT-ACTING ANTIVIRALS [PDF]

Journal of the Egyptian Society of Parasitology, 2018
This study evaluated the effect of diabetic control on achieving sustained virologic response in patients with chronic hepatitis C virus infection who received direct-acting antivirals (Daclatasvir + Sofosbuvir ± Ribavirin). It included 100 patients with
AHMED MOHAMMED, AYMAN GAMIL, REHAM AL-SWAFF, KHALED ELKARMOUTY   +3 more
doaj   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, Christine John, Ralph Link, Hartwig Klinker, Uta Merle, Markus Cornberg, Christoph Sarrazin, Thomas Berg, Heiner Wedemeyer   +10 more
wiley   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis

Gut and Liver, 2019
Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song   +11 more
doaj   +1 more source

Assessment of auditory function in hepatitis “C” patients managed by combination of sofosbuvir and daclatsavir

The Egyptian Journal of Otolaryngology, 2022
Background To evaluate the effect of daclatasvir and sofosbuvir on auditory function in hepatitis C patients. Thirty hepatitis C virus (HCV) patients were included in this study with age ranged from 22 to 55 years.
El-Zahraa M. Meghezel, Mohammed A. Abd Al-Ghaffar, Asmaa Naser Mohammad, Samar M. Mahmoud, Usama M. Abdelaal, Salwa Mourad   +5 more
doaj   +1 more source

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients

Hepatology Research, Volume 56, Issue 5, Page 778-783, May 2026.
ABSTRACT Background and Aims Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first‐line direct‐acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such ...
Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto   +10 more
wiley   +1 more source